Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phase I study results of M7824 for patients with HPV associated cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 510
Rating:

Dr Julius Strauss - Center for Cancer Research, Washington, USA

Dr Strauss speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase 1 study looking at the safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.

He goes on to discuss that the data from the trial of M7824 suggests a manageable safety profile and an overall response rate of 37.5% in patients with HPV associated cancers including a confirmed overall response rate of 45.5% in patients with known HPV disease.
 

Related videos

18.10.18

no rating
For HSCT in Ph-positive ALL

follow us

Breast cancer epidemiology video


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation